These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

858 related items for PubMed ID: 19036752

  • 1. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    Rey D, Hoen B, Chavanet P, Schmitt MP, Hoizey G, Meyer P, Peytavin G, Spire B, Allavena C, Diemer M, May T, Schmit JL, Duong M, Calvez V, Lang JM.
    J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
    [Abstract] [Full Text] [Related]

  • 2. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Masquelier B, Neau D, Boucher S, Lavignolle-Aurillac V, Schrive MH, Recordon-Pinson P, Ragnaud JM, Fleury H.
    Antivir Ther; 2006 Feb; 11(6):827-30. PubMed ID: 17310827
    [Abstract] [Full Text] [Related]

  • 3. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
    Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Saekang N, Pairoj W, Chantratita W.
    J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Ribera E, Rodríguez-Pardo D, Rubio M, Soler A, Pedrol E, Blanco JL, González A, Crespo M, Falcó V, Ocaña I, Deig E, Miró JM, Pahissa A.
    Antivir Ther; 2005 Apr; 10(5):605-14. PubMed ID: 16152754
    [Abstract] [Full Text] [Related]

  • 5. Once-daily dosing of nevirapine in HAART.
    Clotet B.
    J Antimicrob Chemother; 2008 Jan; 61(1):13-6. PubMed ID: 18006524
    [Abstract] [Full Text] [Related]

  • 6. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
    Bickel M, Bodtländer A, Knecht GK, Stephan C, von Hentig N, Kurowski M, Gute P, Klauke S, Lutz T.
    J Antimicrob Chemother; 2009 Dec; 64(6):1260-4. PubMed ID: 19776037
    [Abstract] [Full Text] [Related]

  • 7. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
    Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W.
    Clin Infect Dis; 2007 Feb 01; 44(3):447-52. PubMed ID: 17205457
    [Abstract] [Full Text] [Related]

  • 8. Comment on: High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    Parienti JJ.
    J Antimicrob Chemother; 2009 May 01; 63(5):1080; author reply 1080-1. PubMed ID: 19158108
    [No Abstract] [Full Text] [Related]

  • 9. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
    Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, Luna E, González A, Pedrol E, Lozano L, Ocaña I, Llibre JM, Casiró A, Aranda M, Barrufet P, Martínez-Lacasa J, Miró JM, Badía X, Casado A, Lupo S, Cahn P, Maños M, Estela J.
    Antivir Ther; 2002 Jun 01; 7(2):81-90. PubMed ID: 12212928
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.
    Dominguez S, Ghosn J, Peytavin G, Izzedine H, Wirden M, Ktorza N, Miller M, Aubron-Olivier C, Trylesinski A, Calvez V, Deray G, Katlama C.
    J Med Virol; 2007 Feb 01; 79(2):105-10. PubMed ID: 17177308
    [Abstract] [Full Text] [Related]

  • 11. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
    Piketty C, Gérard L, Chazallon C, Marcelin AG, Clavel F, Taburet AM, Calvez V, Madelaine-Chambrin I, Molina JM, Aboulker JP, Girard PM, Agence Nationale de Recherche sur le SIDA 107-Puzzle 2 Study Group.
    Antivir Ther; 2006 Feb 01; 11(2):213-21. PubMed ID: 16640102
    [Abstract] [Full Text] [Related]

  • 12. Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.
    Smith DE, Chan DJ, Maruszak H, Jeganathan S.
    Int J STD AIDS; 2011 Apr 01; 22(4):228-30. PubMed ID: 21515757
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
    TEmAA ANRS 12109 Study group, Arrivé E, Chaix ML, Nerrienet E, Blanche S, Rouzioux C, Coffie PA, Kruy Leang S, McIntyre J, Avit D, Srey VH, Gray G, N'Dri-Yoman T, Diallo A, Ekouévi DK, Dabis F.
    AIDS; 2009 Apr 27; 23(7):825-33. PubMed ID: 19307941
    [Abstract] [Full Text] [Related]

  • 16. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
    Mocroft A, Phillips AN, Ledergerber B, Katlama C, Chiesi A, Goebel FD, Knysz B, Antunes F, Reiss P, Lundgren JD.
    AIDS; 2006 May 12; 20(8):1141-50. PubMed ID: 16691065
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy.
    Arastéh K, Rieger A, Yeni P, Pozniak A, Boogaerts G, van Heeswijk R, de Béthune MP, Peeters M, Woodfall B.
    Antivir Ther; 2009 May 12; 14(5):713-22. PubMed ID: 19704175
    [Abstract] [Full Text] [Related]

  • 19. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
    Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, Liao Q, Ross L, Johnson J, Shaefer MS, ESS30009 Study.
    J Infect Dis; 2005 Dec 01; 192(11):1921-30. PubMed ID: 16267763
    [Abstract] [Full Text] [Related]

  • 20. Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients.
    Lapadula G, Costarelli S, Quiros-Roldan E, Calabresi A, Izzo I, Carosi G, Torti C.
    Clin Infect Dis; 2008 Apr 01; 46(7):1127-9. PubMed ID: 18444839
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.